chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Loss of conciousness,stiffening, loss of respiration. Respirations begun- heartbeat present.  Spontaneous respirations returned. Given juice and animal crackers.  Blood sugar 110 after those.  BP 100/70.
Mother of patient walked into center escorted by employee. Mother states child "broke out with rash over her body" after getting vaccines from center. Mother states she didn't want to fill out a report. I'll take them to hospital. VAERS report completed with info from immunization record.
My arm started hurting the night after receiving the vaccine, it was bothering me since then. My lower back and right side started hurting the same night of vaccine, this morning it was worse and I was feeling like I wasn't going to make it. I still feel weak.  It was difficult for me for me to get out of bed this morning.
Student presented to receive the HPV (human papilloma vaccine) and inadvertently received the HBV (Hepatitis B vaccine).
Body aches on day 1 after vaccine.  I took aspirin  26 hours after receiving the vaccine.  It seemed to ease the symptoms.  No adverse event on day 2 following vaccine.
Her arm became sore, red and very swollen near site of injection. The redness and swelling went away after 24 hours and soreness after 48 hours.
Pt received Rotateq on 10/5/07.  On 10/9/07, she developed watery diarrhea and on 10/10/07 she developed bloody diarrhea which lasted for a week. Stool cultures sent and were negative for bacteria.
The observation nurse saw pt holding his chest, as he was seated for 15 min wait post injection. He denied past hx of illness or dyspnea. His color was good, and skin warm and dry. BP 96/74 P 100. He did not appear to be in distress. After 15 min, he was transferred to clinic via wheelchair by the school nurse, who called parent.
Within forty minutes of receiving the vaccine, the back of my tongue felt "fat", no other way to describe it. Within an hour, my arms and legs were tingling and felt numb, much like when a leg or arm falls asleep, with intermittent chills running down the limb then gone. I had five episodes of tachycardia on 3-12-21, only two brief episodes today, 3-13-21.  48 hours later and I still experience a brief surge of the numb and tingling feeling, but it's so much better. The vaccination site itched profusely but that has eased.  I began taking Benadryl and Advil approximately four hours after receiving the vaccine and it did help.
fatigue; sore arm; aches; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 25Sep2022 at 14:30 as dose 5 (booster), single (Lot number: GH9693) at the age of 63 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history included: "covid prior vaccination" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 3; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 4; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: PAIN (non-serious) with onset 25Sep2022 at 23:45, outcome "recovered" (Sep2022), described as "aches"; FATIGUE (non-serious) with onset 25Sep2022 at 23:45, outcome "recovered" (Sep2022); PAIN IN EXTREMITY (non-serious) with onset 25Sep2022 at 23:45, outcome "recovered" (Sep2022), described as "sore arm ". Therapeutic measures were not taken as a result of fatigue, pain in extremity, pain.  Additional information: Patient had no other vaccine in four weeks and no other medications in two weeks. It was also reported sore arm 8 hours post-injection, aches and fatigue 12 hours post injection. Events did not result in emergency room visit and physician office visit. Patient did not have covid tested post vaccination, and no known allergies.  No follow-up attempts are possible. No further information is expected.
Patient claims that she experienced EXTREME shooting nerve pain when the Immunization was administered. No redness or swelling after, no visible signs of trauma.  Pt has existing Celliac disease and Chronic nerve and muscle pain.
Patient had localized Injection site reaction. Site began to swell immediately after shot was given. Site was painful red and swollen, approx the size of a golf ball. Site did not bruise. Patient  iced area on and off for 4 days and was fully resolved in approx 10 days with no further problems.
I received my first Pfizer booster for COVID-19 on 11/22/2021. On the evening of 5/31/2022, my throat became scratchy, and I developed a headache. My wife and child had COVID-19 at the time, so I was on the lookout for potential symptoms. I took a home antigen test on 5/31/2022 and got a negative result. On 6/1/2022, I developed head congestion. I still had a sore throat, and I think I still also had a headache. It basically felt like I had a cold, and I had no fever. On 6/1/2022, I took another home test and got a positive result. On 6/2/2022, I had a fever, headache, head congestion, and sore throat. On 6/3/2022, the fever, congestion, and headache were worse, plus I had body aches. I took Sudafed, which helped. On 6/4/2022, I had no fever and no headache, but I was still congested. The symptoms continued for the next few days. On 6/8/2022, I was still congested, but all of the other symptoms were gone. On 6/11/2022, I took another test and got a negative result. I notified my doctor of the situation on 6/1/2022, but he didn't follow up with me. I just treated my symptoms with OTC medicines.
Pt called to states that he had a event of body jerking in the evening at bedtime.  He did not experienced this with his previous doses. He states that he is okay the next day ,just tired but felt the body jerking was severe.
PATIENT COMPLAINED OF ITCHING LOCALIZED ON THE SITE OF ADMINISTRATION. NO SWELLING OR REDNESS VISIBLE. PATIENT WAS CLOSELY MONITORED. AT 12:05PM BP WAS CHECKED AND REGISTERED AT 120/76. AT 12:20 PATIENT INFORMED ADMINISTERING PHARMACIST THAT THE ITCHINESS WAS PRACTICALLY GONE. AT 12:26PM BP WAS CHECKED AGAIN AND REGISTERED AT 122/76. PATIENT WAS RELEASED AT 12:30PM. AND WAS ADVICED TO TAKE BENADRYL AT HOME.
Employee calling to report a reaction after receiving a COVID-19 vaccine.  Vaccine Name -  Pfizer Vaccine Date - ?  9/22/2021 Is this your first or second dose- 2nd dose in the left deltoid Date of symptom onset - ? 9/23/2021 Symptoms - ? fever of 100.1, Bad headache, feeling like she was hit by a bus, and diarrhea Last day of work and shift - ? NA Home remedies- none Any improvement- Diarrhea has resolved Recommendation- Advised employee to take Tylenol or Ibuprofen if not allergic as needed per pack instructions for fever and headache. Also advised employee to monitor for new or worsening symptoms and inform us accordingly Employee voiced understanding Employee of information ? Yes  Employee voiced any concerns ? No  Employee?s questions answered to employee?s satisfaction -Yes
Information has been received from a 30 year old female with no relevant medical history or allergies who in November 2007, was vaccinated with a first dose of GARDASIL vaccine (yeast) (lot number, injection site and route not reported). On unspecified dates the patient was vaccinated with a second and third dose of GARDASIL vaccine (yeast) (lot number, injection site and route not reported). Concomitant therapy included hormonal contraceptives (unspecified). In May 2008, also reported as after receiving the third dose, the patient experienced muscle pain and weakness. The patient sought unspecified medical attention. The patient's muscle pain and weakness persisted. No further information is available.
No additional AE or PQC reported; expired on 14 NOV 2021 and was administered 09 DEC 2021.; This spontaneous report was received from a medical assistant and refers to a 22-year-old female patient. No information regarding the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant medications was provided.  On 09-DEC-2021, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) 0.5 mL, subcutaneously, lot # S036663, expiration date 14-NOV-2021 (dose number and vaccination site were not provided) for prophylaxis. No prescription drug treatment was required. The patient was doing well with no issues. The vaccine did not have any previous temperature excursions, no additional adverse event (AE) was reported.
it leaked out all over; There may have been a crack; The initial case was missing the following minimum criteria: no adverse event. Upon receipt of follow-up information on 10Nov2023, this case now contains all required information to be considered valid.  This is a spontaneous report received from a contactable reporter(s) (Other HCP) from product quality group, Program ID:.  This is a reportable malfunction involving rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown, single (Lot number: HG1755, Expiration Date: May2025).  The following information was reported: DEVICE LEAKAGE (non-serious), outcome "unknown", described as "it leaked out all over". Additional information: it was reported that there was a factory defect with the vaccine. When trying to dilute it, it wasn't sealed and it leaked out all over. It was not given to a patient. One of the techs that is authorized to do shots was doing that. Usually spin the top and it tightens and creates a seal and inject diluent and it mixes up, but it leaked out all over. There may have been a crack. Caller still has the defective product. Sample of the product is available to be returned.  The reporter considered "it leaked out all over" not related to rsv vaccine prot.subunit pref 2v. Causality for "it leaked out all over" was determined associated to device constituent of rsv vaccine prot.subunit pref 2v.  Follow-up attempts are completed. No further information is expected.
VARIVAX underwent a temperature excursion and was administered; This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and gender. On 11-JUN-2021, the patient was vaccinated with a dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot # T029533 exp date 01-SEP-2022) (dose and route not reported) that underwent a temperature excursion. Previous temperature of excursion was 6°F to 14°F (14F) for 2 hours, 14°F to 46°F (45.5F) 1 hour and 30 minutes and 6°F t o14°F (14.4F) for 2 hours.  This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2106USA006064: US-009507513-2106USA006458: US-009507513-2106USA006459: US-009507513-2106USA006460: US-009507513-2106USA006461: US-009507513-2106USA006462: US-009507513-2106USA006463: US-009507513-2106USA006464: US-009507513-2106USA006465: US-009507513-2106USA006466: US-009507513-2106USA006467: US-009507513-2106USA006468: US-009507513-2106USA006469: US-009507513-2106USA006471: US-009507513-2106USA006472: US-009507513-2106USA006473: US-009507513-2106USA006474: US-009507513-2106USA006475: US-009507513-2106USA006476: US-009507513-2106USA006477: US-009507513-2106USA006478: US-009507513-2106USA006479: US-009507513-2106USA006480: US-009507513-2106USA006481: US-009507513-2106USA006482: US-009507513-2106USA006483: US-009507513-2106USA006484: US-009507513-2106USA006485: US-009507513-2106USA006486: US-009507513-2106USA006487: US-009507513-2106USA006488: US-009507513-2106USA006489: US-009507513-2106USA006490: US-009507513-2106USA006491: US-009507513-2106USA006492: US-009507513-2106USA006493: US-009507513-2106USA006494: US-009507513-2106USA006495: US-009507513-2106USA006496: US-009507513-2106USA006497: US-009507513-2106USA006498:
Back pain under ribs, on the right side; pain is sometimes also on the left side and only occurs with activity; pain is severe enough to interfere with daily activities; first dose of Shingrix on 30-OCT-2019. He has not yet received his second dose; Injection site pain; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 30th October 2019, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On 30th October 2019, immediately after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced injection site pain. On an unknown date, the patient experienced back pain, pain upon movement, activities of daily living impaired and incomplete course of vaccination. On an unknown date, the outcome of the injection site pain was recovered/resolved and the outcome of the back pain, pain upon movement and activities of daily living impaired were not recovered/not resolved and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the injection site pain, back pain, pain upon movement and activities of daily living impaired to be related to Shingrix.     Additional Information: GSK Receipt Date: 19-Oct-2022 Reporter's comment: The reporter was the patient.  The patient received Shingrix vaccine on an unknown arm. The patient had not yet received his second dose.  The patient had injection site pain at the time of the injection which was recovered.  Soon after the injection he experienced back pain under his ribs, on the right side which was not recovered.  The patient was not sure of the date for back pain when it was started.  The pain was sometimes also on the left side and had only occurred with activity.  The pain was severe enough to interfere with daily activities.  His doctor and physician's assistant told him they do not think the back pain was due to Shingrix.  He had a CT scan scheduled for today (on the day of reporting).  Nothing else was reported. The consent to follow-up was granted. The reporter may follow up with physician. Additional supportive information: Till the time of reporting the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Information has been received, via the Merck pregnancy registry, from a physician, concerning an 18 year old female patient with asthma, who was pregnant, (approximately 10-14 weeks pregnant), and on 15-MAY-2007 was vaccinated with the first dose, 0.5ml, of Gardasil (Lot #655620/0171U). The physician confirmed that no adverse effect was involved. No further details were reported. Follow up information from a nurse practitioner/certified nurse midwife, indicated the patient's LMP date was 17-MAR-2007 and the estimated date of conception as 31-MAR-2007. The estimated date of delivery was 22-DEC-2007. Additional follow up information indicated that on 03-NOV-2007, the pregnancy resulted in a "premature birth and a low birth weight baby" (gestational week not specified). The infant's (gender not specified) birth weight was less than 5 pounds. The infant continued in the hospital after 1 week, due to feeding difficulties. Additional information has been requested.
Pt called clinic with c/o headache, nausea, chills, blurred vision & pain at injection site. Pt denies fever, difficulty breathing, & redness/swelling/drainage from injection site. Pt reports no other symptoms.
3 inch red spot at injection site with itchiness, patient is treating with hydrocortisone cream and doing well.
Patient received Tdap, boostrix or adacel, unknown by reporter. Urticaria started approximately 34 hours after injection, no other new exposures/allergens
Information has been received from a license vocational nurse (LVN) concerning a patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX (lot # 655290/0959F). The patient had redness, inflammation at the injection site, swollen arm and slight fever after receiving the dose of PNEUMOVAX. The patient then developed hives. The patient sought unspecified medical attention. No further information was provided. This is one of several reports received from the same source. Additional information has been requested.
Subsequent to receiving the first dose of Engerix B the pt experienced a syncopal episode. As of 08/22/2000, the outcome of the event is unknown.
Sore arm within an hour. Next morning I developed a   hot knife- knife like pain in right hip which progressed to both hips by afternoon. Hurt to walk for two days and still painful but less so on day 3 today.
On the 8th day I had a red splotch near injection site and a little soreness on it.
PATIENT IS COMPLAINING THAT ITS HARD TO LIFT UP HER ARM AND AND SHE IS LOOSING SENSITIVITY IN HER RIGHT HAND.
Woke around 8am Saturday March 7th 2015... Noticed patient was trying to scratch through diaper... I changed diaper and noticed small red bumps all of legs and on stomach. Throughout day bumps have appeared more now under arms back of legs and face. Contacted doctor, was told watch for fever and gave advice on public interactions and possible oatmeal bath! It is currently the evening of March 7th 2015 and it's bedtime for patient. No fever is showing on thermometer... But we are continuing to monitor situation.
Got Pfizer as a 1st dose and Moderna as a 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer as a 1st dose and Moderna as a 2nd dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Autoimmune disorder.   On 07-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 07-Nov-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer as a 1st dose and Moderna as a 2nd dose). On 07-Nov-2021, INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer as a 1st dose and Moderna as a 2nd dose) had resolved.            Concomitant medications and treatment information were not provided by reporter.  Patient wants to know if patient should get a third one. Two weeks after the Pfzier dose, patient had a relapse with disease and landed in the ER. Patient thought this was related to the vaccine and that's why patient chose Moderna as a second dose.
RASH AT INJECTION SITE ARM SORE - HIGH WBC ACUTE PROMYELOCYTIC LEUKEMIA.
Pt received 2nd dose pfizer @ 0800 Pt found by observer @ 0802 with increased WOB, pale skin, pt unable to speak in full sentences due to SOB. Lungs sounds assessed and noted to be wheezy, x1 does Epi administered, 911 called. 0803- BP 100/60, HR-100, RR 32, SPO2- 92, Pt breathing improved after 2 mins, pt verbalizes decreased WOB. Second set of vitals- BP 110/70, HR 106, RRR- 20, SpO2, 96%. 0809- AMR arrives and assumes care of pt
Case number PHEH2012US022813 is an initial spontaneous report received from a medical assistant on 15 Nov 2012 and a follow up received from a medical assistant on 17 Dec 2012: This report refers to a 27-year-old female patient. She was given only MenCYW lyophilized conjugate component of MENVEO (batch number M11071 and expiry date: Dec 2013) intramuscularly into her left deltoid on 13 Nov 2012 without being reconstituted with the MenA component. No adverse event was reported following this administration error. Follow up information received from a medical assistant on 17 Dec 2012: Updated the site of vaccination.
fainted and had a seizure immediately following vaccination; fainted and had a seizure immediately following vaccination; This spontaneous report was informed from a company representative who was received information from a physician who refers a female patient who was 18 years old. Her pertinent medical history, concomitant therapies and drug reactions an allergies were unknown by the reporter.    On an unknown date the patient was vaccinated with the first dose of HPV rL1 6 11 16 18 31 45 52 58 VLP vaccine (yeast) (GARDASIL 9), injection indication reported as vaccination, (Concentration, dose, frequency, route, lot number and expiration date were unknown). following vaccination the patient immediately  fainted (syncope) and had a seizure (seizure). It was unknown by the reporter, if the patient sought medical attention, if laboratory diagnostic or studies were performed or if the patient received any treatment due to the event. The outcome of syncope and seizure was unknown.   The causality assessment between HPV rL1 6 11 16 18 31 45 52 58 VLP vaccine (yeast) (GARDASIL 9) administration, and the occurred events was not reported.  Upon internal review, syncope and seizure were determined to be medically significant event.
3 days after vaccination, person was somewhat disoriented. 4th day after vaccination, patient fell, hit head and developed subdural hematoma from which he subsequently died.
This spontaneous report was received from a medical assistant via a company representative and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date (reported as "one year old), the patient was vaccinated with VARIVAX subcuteanous injection (dose, lot# and expiry date were not provided) for prevention of Varicella (Chickenpox). On an unknown date (reported as " and subsequently at eight months old"), the patient developed rash. The rash was later tested for "Chickenpox" but the results were unknown. The outcome of rash is unknown. Causality assessment was not provided.
This case was reported by a healthcare professional (certified medical assistant) via a sales representative and described the occurrence of diffuse rash in a 33-year-old male subject who was vaccinated with BOOSTRIX (GlaxoSmithKline), FLUARIX. On 28 January 2013 at 12:00 the subject received a dose of BOOSTRIX (.5 ml, unknown route, unknown deltoid). On 28 January 2013 the subject received a dose of FLUARIX (unknown route, unknown deltoid). On 28 January 2013, 4 hours after vaccination with BOOSTRIX and FLUARIX, the subject experienced diffuse rash, itching, and raised rash. The subject described the diffuse rash as "raised" and experienced itching on "his trunk, back and both arms." The subject was treated with BENADRYL 50mg. On 30 January 2013, 2 days after vaccination with BOOSTRIX and FLUARIX, the subject reported to the physician's office that he experienced injection site pain; however, it was unclear as to which injection site or both. The subject also reported to the physician's office that the rash had "disappeared, but comes back at night. The BENADRYL helps the rash." The subject was advised to stay on BENADRYL and contact the physician if the rash "persists to come back." At the time of reporting the outcome of the events were unspecified. The healthcare professional considered the events were possibly related to vaccination with BOOSTRIX and FLUARIX.